Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as an executive-level leader in both start-up and mid-size pharma/biotech companies. As founder and CEO of Nezee Therapeutics, she gained critical expertise and insight in the space; she also served as president and head of research and development Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently she serves as an independent board director at Object Pharma and advisory committee member at nonprofit Prostate Cancer Research; she is also a dean advisor at Chapman University School of Pharmacy. In her various roles, Turkey has led and executed FDA registration and commercial strategic plans as well as global development programs; she has invaluable experience in a range of sectors, including neurosciences, pain, cardiovascular, psychiatry, rare diseases, ophthalmology, aesthetics, urology and otology therapeutic areas. In addition, Turkel designed and led an innovative BOTOX(R) chronic migraine registration program for Allergan, now AbbVie Inc. (NYSE: ABBV), which generated more than a billion dollars. “Lexaria is delighted to welcome Dr. Turkel as we continue to position the company for advancement following our recent successful pre-IND meeting with the Food and Drug Administration,” said Lexaria board chair Chris Bunka in the press release. “Catherine’s practical development and regulatory expertise will be of increasing value to Lexaria, and we look forward to working with her.”
To view the full press release, visit https://cnw.fm/JroKp
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
